M. Whitaker

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
M Whitaker, Martin J Whitaker, Martin Whitaker, Martin J. Whitaker
Publication record
47 papers · 904 citations · H-index 14

PAPERS

A quantitative modeling framework to understand the physiology of the hypothalamic-pituitary-adrenal axis and interaction with cortisol replacement therapy
20243 citationsauthor #8
Insights in the maturational processes influencing hydrocortisone pharmacokinetics in congenital adrenal hyperplasia patients using a middle-out approach
20233 citationsauthor #8
Model-Informed Target Morning 17α-Hydroxyprogesterone Concentrations in Dried Blood Spots for Pediatric Congenital Adrenal Hyperplasia Patients
20233 citationsauthor #8
Developing oral chronotherapy for cortisol replacement in congenital adrenal hyperplasia
20236 citationsauthor #1
Home Waking Salivary Cortisone to Screen for Adrenal Insufficiency.
202343 citationsauthor #9
Chronotherapy based on modified-release hydrocortisone to restore the physiological cortisol diurnal rhythm
20228 citationsauthor #1
Exploring Dried Blood Spot Cortisol Concentrations as an Alternative for Monitoring Pediatric Adrenal Insufficiency Patients: A Model-Based Analysis
20225 citationsauthor #7
Screening for adrenal insufficiency using home waking salivary cortisone is accurate and lowers NHS costs
20220 citationsauthor #9
Main Salivary steroid collection in children under conditions replicating home sampling.
20228 citationsauthor #4
Salivary sampling in neonates, infants, and young children: glucocorticoid stability under different conditions and the introduction of a novel collection technique
20220 citationsauthor #4
An oral lipidic native testosterone formulation that is absorbed independent of food
20213 citationsauthor #9
Development and verification of an endogenous PBPK model to inform hydrocortisone replacement dosing in children and adults with cortisol deficiency.
202113 citationsauthor #4
A Prospective Study of Children Aged 0–8 Years with CAH and Adrenal Insufficiency Treated with Hydrocortisone Granules
202028 citationsauthor #3
Response to 'Hydrocortisone suspension formulations are not necessarily the same in the treatment of children with congenital adrenal hyperplasia'.
20201 citationsauthor #5
Paediatric population pharmacokinetic modelling to assess hydrocortisone replacement dosing regimens in young children.
202010 citationsauthor #5
Physiologically based pharmacokinetic modelling to inform dosing in adrenal insufficiency and congenital adrenal hyperplasia
20200 citationsauthor #1
A Biopredictive In Vitro Approach for Assessing Compatibility of a Novel Pediatric Hydrocortisone Drug Product within Common Pediatric Dosing Vehicles
202023 citationsauthor #7
Glucocorticoids regulate AKR1D1 activity in human liver in vitro and in vivo
20209 citationsauthor #7
Differential regulation of 5[beta]-reductase (AKR1D1) expression and activity by glucocorticoids in human and rodent liver
20190 citationsauthor #8
P93 Semi-mechanistic modelling of hydrocortisone pharmacokinetics in paediatric patients with adrenal insufficiency
20190 citationsauthor #7
Prospective, Open-Label, Long-Term Follow-Up of Neonates and Young Children with Adrenal Insufficiency Treated with Hydrocortisone Granules
20190 citationsauthor #3
The circadian rhythm of corticosteroid‐binding globulin has little impact on cortisol exposure after hydrocortisone dosing
201912 citationsauthor #4
Salivary Cortisone to Estimate Cortisol Exposure and Sampling Frequency Required Based on Serum Cortisol Measurements
201820 citationsauthor #3
Adrenal Insufficiency in Young Children: a Mixed Methods Study of Parents’ Experiences
201814 citationsauthor #5
Biorelevant in vitro assessment of dissolution and compatibility properties of a novel paediatric hydrocortisone drug product following exposure of the drug product to child‐appropriate administration fluids
201822 citationsauthor #3
Predicting Cortisol Exposure from Paediatric Hydrocortisone Formulation Using a Semi-Mechanistic Pharmacokinetic Model Established in Healthy Adults
201815 citationsauthor #6
Accuracy of hydrocortisone dose administration via nasogastric tube
201812 citationsauthor #2
Poor compliance and increased mortality, depression and healthcare costs in patients with congenital adrenal hyperplasia.
201865 citationsauthor #5
Biorelevant dissolution and compatibility of hydrocortisone granules following exposure to water, breast-, whole- and artificial (formula) milk
20180 citationsauthor #3
Long-term Follow-up of Safety and Disease Control for Hydrocortisone Granules Designed to give Age-appropriate Dosing with Taste Masking to Children with Adrenal Insufficiency
20180 citationsauthor #3
Absorption and tolerability of taste‐masked hydrocortisone granules in neonates, infants and children under 6 years of age with adrenal insufficiency
201855 citationsauthor #2
Quality of compounded hydrocortisone capsules used in the treatment of children.
201749 citationsauthor #4
University of Birmingham Modified release and conventional glucocorticoids and diurnal androgen excretion in congenital adrenal hyperplasia
20170 citationsauthor #9
Impact of food, alcohol and pH on modified-release hydrocortisone developed to treat congenital adrenal hyperplasia
20173 citationsauthor #4
Modified-Release and Conventional Glucocorticoids and Diurnal Androgen Excretion in Congenital Adrenal Hyperplasia
201655 citationsauthor #8
Salivary Cortisone Reflects Cortisol Exposure Under Physiological Conditions and After Hydrocortisone.
2016106 citationsauthor #3
A model for measuring the health burden of classic congenital adrenal hyperplasia in adults
20169 citationsauthor #3
Patients with Congenital Adrenal Hyperplasia have Significantly Higher Healthcare Utilisation than the General Paediatric Population
20160 citationsauthor #5
A phase 2 study of Chronocort, a modified-release formulation of hydrocortisone, in the treatment of adults with classic congenital adrenal hyperplasia.
2015141 citationsauthor #4
Development and testing in healthy adults of oral hydrocortisone granules with taste masking for the treatment of neonates and infants with adrenal insufficiency.
201541 citationsauthor #1
Modelling the salivary cortisone to serum cortisol inter-relationship to predict serum cortisol under physiological conditions and after hydrocortisone
20150 citationsauthor #4
Alternative pathway synthesis dominates androgen production in patients with congenital adrenal hyperplasia and is decreased by Chronocort ® more than by conventional glucocorticoid therapy
20150 citationsauthor #6
An oral multiparticulate, modified‐release, hydrocortisone replacement therapy that provides physiological cortisol exposure
2014119 citationsauthor #1
Development of oral hydrocortisone granules with taste masking for the treatment of neonates and infants with adrenal insufficiency
20140 citationsauthor #2
University of Birmingham A phase 2 study of Chronocort, a modified-release formulation of hydrocortisone, in the treatment of adults with classic congenital adrenal hyperplasia
20140 citationsauthor #4
Chronocort[reg], a multiparticulate modified release hydrocortisone formulation, shows dose linearity and twice daily dosing provides physiological cortisol exposure
20130 citationsauthor #2
A hydrocortisone core comprising a coating of a pH sensitive enteric polymer for controlled release
20130 citationsauthor #3

TIMELINE

2013 0 citations

2014 119 citations

2015 182 citations

2016 170 citations

2017 52 citations

2018 203 citations

2019 12 citations

2020 71 citations

2021 16 citations

2022 21 citations

2023 55 citations

2024 3 citations

COAUTHOR MAP

CONCEPT FOOTPRINT